Showing results (301-310 of 306) with videos related to
Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 306 results.
Signal Transduction and Targeted Therapy|October 22, 2024
Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trialsSai-Wei Huang, Wei Jiang, Sha Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2026
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER TrialsSai-Wei Huang, Ye-Lin Liang, Ya-Lan Tao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuo-Xi Hong, Fei Xu, Wen Xia, et al.Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.JAMA|August 21, 2025
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial, Cheng Xu, Xiao-Yu Liang, et al.Pageof 31